DifGen Pharmaceuticals

What DifGen Pharmaceuticals does

DifGen Pharmaceuticals is a privately held U.S. pharmaceutical company focused on complex and differentiated generics across the full dosage-form spectrum, including oral solids, softgels, parenteral suspensions, long-acting injectables, complex ophthalmic products, transdermal systems, oral dissolvable films, and drug-device combinations. The company operates a dual-shore model anchored by a 55,000 sq. ft. R&D Centre of Excellence in Hyderabad, India and a 455,000 sq. ft. U.S. manufacturing footprint through its wholly owned Aveva Drug Delivery Systems subsidiary (acquired April 2023), which produces over 300 million transdermal patches and oral dissolvable film units annually for Rx, OTC, and controlled substances. DifGen's R&D team includes more than 100 scientists with expertise spanning biologics, biosimilars, small-molecule generics, OTC therapies, and drug-device combinations.

The company monetizes through three streams. First, DifGen develops and commercializes FDA-approved complex generics such as Fluorometholone Ophthalmic Suspension 0.1% (approved Feb 2026), Mesalamine Extended-Release Capsules (approved Mar 2026, second consecutive first-cycle approval) and Nintedanib Soft Gel Capsules (approved Apr 2026 in collaboration with Apotex Inc., therapeutically equivalent to Ofev); U.S. commercialization of these products is executed through channel partners such as Apotex. Second, it offers contract manufacturing organization (CMO) services for transdermal and oral dissolvable film products across Rx, OTC and controlled substances. Third, it participates in collaborative drug development and GMP manufacturing scale-up agreements with biotech partners, most notably the JKB-122 (Lodonal) program with Biostax Corp (Attune Biotech) for Phase 2b/3 clinical assets.

DifGen is headquartered in Miramar, Florida (parent entity DifGen Pharmaceuticals LLC) and operates a wholly owned India subsidiary (DifGen Pharmaceuticals Pvt. Ltd.) in Hyderabad. The company is founder-controlled, with Ramandeep Singh Jaj and Santhanakrishnan Srinivasan serving as Co-CEOs, and shows no disclosed institutional ownership, public listing, or external funding rounds in the available data. The near-term strategic posture is centered on converting a recent cluster of FDA approvals into commercial revenue through partner-led distribution, scaling CMO/co-development service revenue, and expanding capacity via the March 2024 acquisition of an FDA-registered manufacturing facility.

Name

DifGen Pharmaceuticals

Legal name

DifGen Pharmaceuticals LLC

Website

https://difgen.com

Company type

Private

Operating status

Operating

Headcount range

101–250 employees

Short description

DifGen Pharmaceuticals is a privately held U.S. complex-generics manufacturer operating across the full dosage-form spectrum, with R&D in India and U.S. manufacturing via its Aveva Drug Delivery Systems subsidiary, serving U.S. healthcare distributors and biotech partners through FDA-approved generic products, CMO services, and collaborative drug-development programs.

Ownership category

akta.pro rank

Product category

Complex Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Complex Generics (e.g., inhalation, transdermal, liposomal) (HLAIABAB)

akta.pro secondary industries

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Complex generic pharmaceuticals
• Transdermal drug delivery
• Contract manufacturing services
• Generic drug development
• Ophthalmic generics

Headquarters

HQ city

Princeton

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Generic Pharmaceutical Product Sales: DifGen develops and commercializes complex generic pharmaceuticals, earning revenue through FDA-approved ANDA products marketed and distributed to the U.S. healthcare market via partners such as Apotex Inc. Recent approvals include Nintedanib Soft Gel Capsules, Mesalamine Extended-Release Capsules, and Fluorometholone Ophthalmic Suspension.
2. Contract Manufacturing Organization (CMO) Services: DifGen provides end-to-end manufacturing services as a CMO partner, producing pharmaceutical products for other companies including complex drug delivery dosage forms, transdermal patches, and oral dissolvable films. Revenue is generated through manufacturing fees for client products.
3. Collaborative Drug Development and Manufacturing: DifGen participates in multi-company collaborations for drug development and GMP manufacturing scale-up, contributing formulation development and manufacturing capabilities in exchange for development milestones and future product revenue streams.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

DifGen Pharmaceuticals develops, manufactures, and commercializes complex and differentiated generic pharmaceuticals across all major dosage forms, including injectables, ophthalmics, transdermal patches, oral dissolvable films, soft gelatin capsules, and drug-device combinations. The company also provides contract manufacturing organization (CMO) services and participates in collaborative formulation development for biotech partners. Its FDA-approved generic portfolio includes Nintedanib Soft Gel Capsules, Mesalamine Extended-Release Capsules, and Fluorometholone Ophthalmic Suspension.

Product overview

DifGen Pharmaceuticals is a healthcare technology firm providing comprehensive solutions from product development to commercial manufacturing and supply of generic pharmaceuticals. The company operates a complex generics portfolio that includes FDA-approved products such as Nintedanib Soft Gel Capsules (partnered with Apotex), Mesalamine Extended-Release Capsules, and Fluorometholone Ophthalmic Suspension. Following the April 2023 acquisition of Aveva Drug Delivery Systems Inc., DifGen enhanced its capabilities in advanced transdermal systems and oral dissolvable films, producing over 300 million patches annually. The company also supports clinical development programs including JKB-122 (Lodonal™), contributing formulation development and GMP manufacturing services. DifGen's infrastructure spans a 55,000 sq. ft. R&D Centre of Excellence in India and 455,000 sq. ft. U.S. manufacturing footprint.

Differentiator

Problem solved

Functional benefit

Brands

• Aveva Drug Delivery Systems: Subsidiary specializing in transdermal delivery systems and oral dissolvable films, producing over 300 million patches annually for Rx, OTC, and controlled substances

Products and services

• Nintedanib Soft Gel Capsules
• Mesalamine Extended-Release Capsules
• Fluorometholone Ophthalmic Suspension, 0.1%
• Contract Manufacturing Organization (CMO) Services
• JKB-122 (Lodonal) Collaborative Development Program
• Complex Generic Pharmaceuticals Portfolio

Quantifiable outcome

• Second consecutive first-cycle FDA approval for Mesalamine Extended-Release Capsules
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered minor and core.

• Callan JMB Inc.minorStrategic or Co-development Partner · 17 April 2026Callan JMB Inc. serves as an independent infrastructure and oversight partner in the multi-company collaboration supporting U.S.-based manufacturing scale-up for JKB-122 (Lodonal). DifGen is involved in manufacturing oversight for the JKB-122 Long COVID drug trial collaboration.
• Apotex Inc.coreChannel Partner/ Reseller/ Distributor · 9 April 2026DifGen and Apotex Inc. collaborated on FDA approval of generic Nintedanib Soft Gel Capsules (100 mg and 150 mg), therapeutically equivalent to Ofev. Apotex received final FDA approval and holds responsibility for marketing and distributing the approved product to the U.S. healthcare market, representing an expansion of DifGen's complex generics portfolio.
• Biostax Corp (Attune Biotech)coreStrategic or Co-development Partner · 27 March 2026DifGen participates in a multi-company collaboration supporting U.S.-based manufacturing scale-up for JKB-122 (Lodonal), an immune restoration platform being advanced by Biostax Corp (Attune Biotech) toward Phase 2b/3 clinical development. DifGen and Aveva Drug Delivery Systems lead formulation development and GMP manufacturing expansion across multiple dose strengths and indications. Attune Biotech's lead PASC program has received FDA authorization to proceed under an active IND.
• Aveva Drug Delivery Systems Inc.coreStrategic or Co-development Partner · 1 April 2023In April 2023, DifGen Pharmaceuticals LLC acquired Aveva Drug Delivery Systems Inc. to enhance research and manufacturing capabilities for complex drug delivery dosage forms, establish a U.S.-based manufacturing hub, and boost supply chain resilience. Aveva specializes in manufacturing transdermal delivery systems and oral dissolvable films, producing over 300 million patches annually.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Dr. Reddy's Laboratories: India-based global pharmaceutical company with a substantial complex generics portfolio across sterile injectables, transdermal patches, and specialty formulations. Comparable in integrated R&D-manufacturing model, U.S. ANDA strategy, and API-to-finished-product vertical integration.
• Apotex Inc. Canadian-headquartered global generic pharmaceutical manufacturer and DifGen's primary U.S. distribution partner. Apotex develops and markets complex generics across dosage forms, directly comparable in therapeutic categories and U.S. commercialization model.
• Endo International: U.S.-headquartered specialty pharmaceutical company with a meaningful complex generics portfolio including injectables, transdermals, and ophthalmics. Comparable in dosage form breadth and U.S. regulatory strategy, though currently undergoing significant restructuring.
• Zydus Lifesciences: India-based pharmaceutical manufacturer with significant U.S. generic presence including transdermals, injectables, and complex oral dosage forms. Comparable in India-based R&D scale, broad dosage form capabilities, and U.S. ANDA strategy.
• Glenmark Pharmaceuticals: India-headquartered global pharmaceutical company with a complex generics portfolio spanning dermatology, respiratory, and oncology. Comparable in India-U.S. operational model and focus on differentiated generics rather than commodity molecules.
• Hikma Pharmaceuticals: U.S.-listed specialty pharmaceutical company focused on complex generics, injectables, and branded specialty products. Comparable in complex generics focus, FDA-cGMP manufacturing footprint, and U.S. distribution through channel partners.
• Aurobindo Pharma: India-based global generic pharmaceutical manufacturer with a large complex generics portfolio including injectables, transdermals, and ophthalmics. Comparable in India-U.S. hybrid cost structure, broad dosage form coverage, and complex ANDA pipeline depth.
• Lupin Pharmaceuticals: India-based global pharmaceutical company with strong U.S. generic presence across complex generics, specialty, and biosimilars. Comparable in India-U.S. operating model, complex ANDA pipeline, and dosage form diversity including transdermals and injectables.

Broad incumbents

• Sandoz (Novartis): Global leader in generic pharmaceuticals and biosimilars with extensive complex generics, injectables, and specialty portfolio. Represents the incumbent scale and regulatory reach DifGen competes against in the U.S. complex generics market.
• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with broad portfolio across simple and complex generics, biosimilars, and specialty medicines. DifGen's complex generics approach targets similar therapeutic areas but at materially smaller scale and narrower product breadth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/difgen

Revenue estimate

Valuation estimate

Number of profiles

Profiles23 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DifGen Pharmaceuticals